CervoMed Soars 60.24% on Positive DLB Trial Data

CervoMed's stock surged by 60.24% in pre-market trading on July 28, 2025, driven by the release of positive data from the 32-week extension phase of its Phase 2b RewinD-LB trial for neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB).

The trial demonstrated a 54% reduction in the risk of clinically significant worsening in patients treated with neflamapimod compared to the control group. This reduction improved to 64% in patients with minimal Alzheimer's Disease co-pathology. The study also showed a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP), a biomarker of neurodegeneration, at week 32. Additionally, the new capsule formulation of neflamapimod achieved target plasma concentrations, resulting in a 40% lower rate of clinically meaningful worsening compared to the old capsules.

CervoMed plans to meet with the FDA in the fourth quarter of 2025 to discuss the design of the Phase 3 trial for this potential treatment. The company's CEO, John Alam, expressed confidence in the drug's potential to significantly impact the clinical progression of DLB, a condition with limited treatment options. The upcoming FDA meeting and Phase 3 plans position CervoMed to potentially address a substantial unmet need in a condition affecting millions worldwide.